Tham khảo Estriol succinate

  1. 1 2 3 4 5 Kuhl H (2005). “Pharmacology of estrogens and progestogens: influence of different routes of administration” (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  2. 1 2 R. S. Satoskar; S. D. Bhandarkar &nirmala N. Rege (1973). Pharmacology and Pharmacotherapeutics. Popular Prakashan. tr. 934–. ISBN 978-81-7991-527-1.
  3. 1 2 Axel Kleemann; Jürgen Engel (2001). Pharmaceutical substances: syntheses, patents, applications. Thieme. tr. 786. ISBN 978-3-13-558404-1.
  4. ↑ Lauritzen C (tháng 11 năm 1987). “Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints”. Horm. Metab. Res. 19 (11): 579–84. doi:10.1055/s-2007-1011886. PMID 3428874.
  5. ↑ Ali ES, Mangold C, Peiris AN (tháng 9 năm 2017). “Estriol: emerging clinical benefits”. Menopause. 24 (9): 1081–1085. doi:10.1097/GME.0000000000000855. PMID 28375935.
  6. ↑ Lommen, Erin; Mead, Jay H (2013). “Estriol; the 'Good' Estrogen Advances and Updates in its Clinical Uses”. Journal of Restorative Medicine. 2 (1): 45–52. doi:10.14200/jrm.2013.2.0103. ISSN 2165-7971.
  7. 1 2 3 4 J. Elks (ngày 14 tháng 11 năm 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. tr. 899. ISBN 978-1-4757-2085-3.
  8. ↑ Winnifred Berg Cutler; Celso-Ramón García (1984). The medical management of menopause and premenopause: their endocrinologic basis. Lippincott Williams & Wilkins. tr. 31. ISBN 978-0-397-50631-6.
  9. ↑ Clark JH, Markaverich BM (1983). “The agonistic and antagonistic effects of short acting estrogens: a review”. Pharmacol. Ther. 21 (3): 429–53. doi:10.1016/0163-7258(83)90063-3. PMID 6356176.
  10. 1 2 3 4 Index Nominum 2000: International Drug Directory. Taylor & Francis. tháng 1 năm 2000. tr. 407–. ISBN 978-3-88763-075-1.
  11. 1 2 3 4 https://www.drugs.com/international/estriol.html
  12. ↑ Lauritzen C, Velibese S (tháng 9 năm 1961). “Clinical investigations of a long-acting oestriol (polyoestriol phosphate)”. Acta Endocrinol. 38 (1): 73–87. doi:10.1530/acta.0.0380073. PMID 13759555.
  13. ↑ Bachmann FF (tháng 1 năm 1971). “Behandlung klimakterisher Beschwerden mit Polyöstriolphosphat” [Treatment of menopausal complaints with polyoestriol-phosphate. Experiences with Gynäsan injections]. Munch Med Wochenschr (bằng tiếng Đức). 113 (5): 166–9. PMID 5107471.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  14. ↑ A. Labhart (ngày 6 tháng 12 năm 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. tr. 548, 551. ISBN 978-3-642-96158-8. The polymer of estradiol or estriol and phosphoric acid has an excellent depot action when given intramuscularly (polyestriol phosphate or polyestradiol phosphate) (Table 16). Phosphoric acid combines with the estrogen molecule at C3 and C17 to form a macromolecule. The compound is stored in the liver and spleen where the estrogen is steadily released by splitting off of the phosphate portion due to the action of alkaline phosphatase. [...] Conjugated estrogens and polyestriol and estradiol phosphate can also be given intravenously in an aqueous solution. Intravenous administration of ovarian hormones offers no advantages, however, and therefore has no practical significance. [...] The following duarations of action have been obtained with a single administration (WlED, 1954; LAURITZEN, 1968): [...] 50 mg polyestradiol phosphate ~ 1 month; 50 mg polyestriol phosphate ~ 1 month; 80 mg polyestriol phosphate ~ 2 months.
  15. ↑ S. Campbell (ngày 6 tháng 12 năm 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–ngày 26 tháng 11 năm 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. tr. 395–. ISBN 978-94-011-6165-7. In the Federal Republic of Germany between 10 and 20% of all climacteric women are on estrogen treatment. We have the following oral estrogens for a treatment. (t) Conjugated estrogens, (2) estradiol valerate, (3) ethinyl-estradiol and its cyclopentyl-enol ether, (4) stilbestrol, (5) ethinyl-estradiol-methyltestosterone, (6) estriol and estriol succinate, most of them as coated tablets. Several long acting injectable preparations are available: several esters of combined estradiol-testosterone, one of estradiol-dehydroepiandrosterone enanthate and a prolonged polyestriol phosphate are also available. Lastly, depot injections of estradiol- and stilbestrol-esters are on the market.
  16. 1 2 William Andrew Publishing (ngày 22 tháng 10 năm 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. tr. 1481–. ISBN 978-0-8155-1856-3.
  17. 1 2 I.K. Morton; Judith M. Hall (ngày 6 tháng 12 năm 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. tr. 114–. ISBN 978-94-011-4439-1.
  18. ↑ https://adisinsight.springer.com/drugs/800026520